Argenx SE Net Debt Growth & History (ARGX)
Argenx SE's net debt was −$3.44B for fiscal 2025.
View full Argenx SE company overviewArgenx SE annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$3.44B | −$1.98B | — |
| 2024 | 2024-12-31 | −$1.46B | $560.8M | — |
| 2023 | 2023-12-31 | −$2.02B | −$1.23B | — |
| 2022 | 2022-12-31 | −$788.3M | $534.9M | — |
| 2021 | 2021-12-31 | −$1.32B | −$116.1M | — |
| 2020 | 2020-12-31 | −$1.21B | −$842.3M | — |
| 2019 | 2019-12-31 | −$364.8M | — | — |
Argenx SE quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$3.54B | −$1.49B | — |
| Q4 2025 | 2025-12-31 | −$3.44B | −$1.98B | — |
| Q2 2025 | 2025-06-30 | −$2.04B | −$649.5M | — |
| Q4 2024 | 2024-12-31 | −$1.46B | $560.8M | — |
| Q2 2024 | 2024-06-30 | −$1.39B | −$294.0M | — |
| Q4 2023 | 2023-12-31 | −$2.02B | −$1.23B | — |
| Q2 2023 | 2023-06-30 | −$1.10B | $258.3M | — |
| Q4 2022 | 2022-12-31 | −$788.3M | $534.9M | — |
| Q2 2022 | 2022-06-30 | −$1.36B | $216.4M | — |
| Q4 2021 | 2021-12-31 | −$1.32B | −$116.1M | — |
| Q2 2021 | 2021-06-30 | −$1.57B | — | — |
| Q4 2020 | 2020-12-31 | −$1.21B | −$842.3M | — |
| Q4 2019 | 2019-12-31 | −$364.8M | — | — |
Argenx SE net debt trends
Over the last five fiscal years, Argenx SE's net debt decreased from −$1.21B to −$3.44B, a change of −$2.24B. The latest reported quarter, Q2 2026, shows −$3.54B.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Argenx SE source filings ↗Community posts
Argenx sales expand as additional clinical and regulatory work advances
Argenx ($ARGX) reported third-quarter 2026 product sales of approximately $1.7 billion, an increase of 54% from a year earlier and 13% from the preceding quarter. Net profit attributable to shareholders increased to $506 million from $344 m ...